



## Laboratory and Genetic Testing for Use of Fluoropyrimidine Chemotherapy (5-FU and Capecitabine) in Patients with Cancer

Published: 02/01/2024

Next Review: 11/2024

Last Review: 12/2023

Medicare Link(s) Revised: 02/01/2024

### IMPORTANT REMINDER

The Medicare Advantage Medical Policy manual is not intended to override the member Evidence of Coverage (EOC), which defines the insured's benefits, nor is it intended to dictate how providers are to practice medicine. Physicians and other health care providers are expected to exercise their medical judgment in providing the most appropriate care for the individual member.

The Medicare Advantage Medical Policies are designed to provide guidance regarding the decision-making process for the coverage or non-coverage of services or procedures in accordance with the member EOC and the Centers of Medicare and Medicaid Services (CMS) policies, when available. In the event of a conflict, applicable CMS policy or EOC language will take precedence over the Medicare Advantage Medical Policy. In the absence of CMS guidance for a requested service or procedure, the health plan may apply their Medical Policy Manual or MCG™ criteria, both of which are developed with an objective, evidence-based process using scientific evidence, current generally accepted standards of medical practice, and authoritative clinical practice guidelines.

Medicare and EOCs exclude from coverage, among other things, services or procedures considered to be investigational, cosmetic, or not medically necessary, and in some cases, providers may bill members for these non-covered services or procedures. Providers are encouraged to inform members in advance when they may be financially responsible for the cost of non-covered or excluded services.

## DESCRIPTION

Tests to guide fluoropyrimidine dosing and/or treatment choice in patients with cancer have been proposed. Dosing of 5-fluorouracil (5-FU) in cancer patients to a predetermined area under the curve (AUC) target has been proposed as a method to reduce variability in systemic exposure to 5-FU, reduce toxicity, and maximize tumor response. Also available is genetic testing for variants affecting 5-FU metabolism in order to determine dosing of 5-FU and capecitabine. Genetic variants may affect activity of enzymes involved in 5-FU metabolism. Currently available genetic tests assess specific variants in genes encoding dihydropyrimidine reductase (DPYD) and thymidylate synthase (TYMS), enzymes in the catabolic and anabolic pathways of 5-FU metabolism, respectively.

## MEDICARE ADVANTAGE POLICY CRITERIA

CMS Coverage Manuals\*      None

<b>National Coverage Determinations (NCDs)*</b>	None
<b>Noridian Healthcare Solutions (Noridian) Local Coverage Determinations (LCDs) and Articles (LCAs)*</b>	<p>For <b>DPYD variant testing offered by laboratories in the health plan's service area:</b></p> <ul style="list-style-type: none"> <li>✓ MolDX: Pharmacogenomics Testing (<a href="#">L38337</a>) (The companion article A57385 can be accessed directly from the LCD. <b>The LCA provides actionable drug-gene details.</b>) (Laboratories in AK, ID, OR, WA, UT, AZ, MT, ND, SD, WY) (Also note the "Special Documentation Requirements" section in the LCD.)</li> <li>✓ MolDX: Pharmacogenomics Testing (<a href="#">L38335</a>) (The companion article <a href="#">A57385</a> provides actionable drug-gene details. (Laboratories in CA and NV) (Also note the "Special Documentation Requirements" section in the LCD.)</li> </ul> <p>For <b>TYMS variant testing offered by laboratories in the health plan's service area:</b></p> <ul style="list-style-type: none"> <li>✓ Noridian J-F web page for MolDX <a href="#">Approved Gene Testing (M00041)</a> (For laboratories in the health plan's service area, as well as laboratories in AK, AZ, MT, ND, SD, WY – search by gene name)</li> <li>✓ Noridian J-E web page for <a href="#">Approved Gene Testing</a> (For laboratories in CA and NV)</li> </ul> <p><i>TYMS testing is listed as an approved test on both web pages. If documentation clearly indicates how the test results are expected to be promptly used by the treating physician to treat and manage a specific medical problem, this testing may be considered medically necessary.</i></p>
<b>Non-Noridian Healthcare Solutions LCDs and LCAs*</b>	<p>For <b>DPYD</b> and/or <b>TYMS</b> gene testing performed in other jurisdictions:</p> <ul style="list-style-type: none"> <li>✓ Billing and Coding: Molecular Pathology Procedures (<a href="#">A56199</a>) (For performing laboratories in IL, MN, WI, CT, NY, ME, MA, NH, RI, VT) (Look for the gene and/or CPT code in the Group 3 Non-covered Codes section)</li> </ul>

\*\*Scroll to the "Public Version(s)" section at the bottom of the LCD for links to prior versions if necessary.

**POLICY GUIDELINES**

**REQUIRED DOCUMENTATION**

The information below **must** be submitted for review to determine whether policy criteria are met. If any of these items are not submitted, it could impact our review and decision outcome:

- The specific name of the genetic or diagnostic laboratory test;
- Name of the performing laboratory;
- The exact gene(s) being tested;
- Applicable CPT and/or HCPCS code(s);
- Brief explanation and medical records documenting how the results of this testing is expected to guide treatment decisions relevant to the member’s personal medical history.

## REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratories offering such tests as a clinical service must meet the general regulatory standards of the Clinical Laboratory Improvement Act (CLIA) and must be licensed by CLIA for high-complexity testing.

## CROSS REFERENCES

[Genetic and Molecular Diagnostics – Single Gene or Variant Testing](#), Genetic Testing, Policy No. M-20

[Chemoresistance and Chemosensitivity Assays \(CSRAs\)](#), Laboratory, Policy No. M-06

## REFERENCES

1. [HCPCS Public Meeting Agenda Item #19](#), May 25, 2011, page 38
2. Noridian Medicare Part B Jurisdiction F (J-F) Website:  
<https://med.noridianmedicare.com/web/jfb/policies/moldx>
3. Medicare Benefit Policy Manual, Ch. 15, [§80.1 - Clinical Laboratory Services](#)
4. Social Security Act §1862(a)(1)(A) [http://www.ssa.gov/OP\\_Home/ssact/title18/1862.htm](http://www.ssa.gov/OP_Home/ssact/title18/1862.htm)

## CODING

**NOTE:** HCPCS code S3722 is a Medicare Status “I” code, and therefore, is not valid for Medicare or Medicare Advantage use.

Codes	Number	Description
CPT	81232	<i>DPYD</i> (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5-FU and capecitabine drug metabolism), gene analysis, common variant(s) (eg, *2A, *4, *5, *6)
	81346	<i>TYMS</i> (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)
	84999	Unlisted chemistry procedure

---

<b>Codes</b>	<b>Number</b>	<b>Description</b>
<b>HCPCS</b>	S3722	Dose optimization by area-under-the-curve (AUC) analysis for infusional 5-fluorouracil (5-FU) <i>(Not valid for Medicare purposes)</i>

---

**\*IMPORTANT NOTE:** Medicare Advantage medical policies use the most current Medicare references available at the time the policy was developed. Links to Medicare references will take viewers to external websites outside of the health plan's web control as these sites are not maintained by the health plan.